Chinese hamster ovary cells (CHO) have been the most commonly used mammalian host for large-scale commercial production of therapeutic proteins. As the industry is moving towards larger batches, higher cell densities and continuous production, FUNDALOOP® offers the ideal solution to the aforementioned problems with its high flow rate and multicyclic, quasi-continuous discharge of biomass. Due to its typically high filtrate quality, FUNDALOOP® furthermore reduces the strain on subsequent downstream processing (DSP) equipment.
Being the microorganism of choice for most gene cloning experiments, Escherichia coli (E. Coli) has a long and successful history in the biotechnology industry. Due to its high growth rate and its ability to conveniently host foreign DNA, it is currently the most widely used microorganism for producing modified plasmid DNA (pDNA). With the surge of personalized medicine in recent years, pDNA plays a critical role in the production of next-generation vaccines and cell and gene therapies.
E. Coli however lacks the ability to secrete the product into the extracellular space which in turn necessitates a cell lysis step. This poses a substantial challenge in DSP since the lysate precipitates and forms a difficult broth where depth filters are rendered ineffective and centrifugal filters impose high operation and maintenance costs.
Unlike depth filters and due to its innovative design, the FUNDALOOP® is not susceptible to clogging and offers a powerful tool for efficiently clarifying E. Coli lysates.
